EP2846788A1 - Utilisation de composés pour le traitement de la douleur - Google Patents

Utilisation de composés pour le traitement de la douleur

Info

Publication number
EP2846788A1
EP2846788A1 EP13721770.9A EP13721770A EP2846788A1 EP 2846788 A1 EP2846788 A1 EP 2846788A1 EP 13721770 A EP13721770 A EP 13721770A EP 2846788 A1 EP2846788 A1 EP 2846788A1
Authority
EP
European Patent Office
Prior art keywords
pain
compound
group
amino
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13721770.9A
Other languages
German (de)
English (en)
Inventor
Henrik Nilsson
Shane Mcmanus
Arif MUHAMED
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akron Molecules AG
Original Assignee
Akron Molecules AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akron Molecules AG filed Critical Akron Molecules AG
Priority to EP13721770.9A priority Critical patent/EP2846788A1/fr
Publication of EP2846788A1 publication Critical patent/EP2846788A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • ester hemifumarate or TAF; or GS- 7340-03
  • A, D, E and G are identical or different and represent hydro ⁇ gen, halogen, nitro, cyano, hydroxyl, carboxyl, trifluoromethyl , trifluoromethoxy or straight-chain or branched alkyl, alkoxy or alkoxycarbonyl each having up to 5 carbon atoms,
  • R 5 denotes hydrogen
  • X has the meaning of R 4 indicated above and can be identical to or different from this meaning
  • A, D, E and G are identical or different and represent hydro ⁇ gen, halogen, nitro, cyano, hydroxyl, carboxyl, trifluoromethyl , trifluoromethoxy or straight-chain or branched alkyl, alkoxy or alkoxycarbonyl each having up to 5 carbon atoms,
  • R 3 represents radicals of the formulae
  • R 7 and R 8 denote hydrogen
  • R 1 represents hydrogen atom or a C 1 -C4 alkoxy group
  • R 2 and R 3 independently represent hydrogen atom, a C 1 -C22 alkyl group, or 2 , 2 , 2-trifluoroethyl group
  • R 4 represents hydrogen atom or methyl group.
  • the inventive compound is Famciclovir (Syn ⁇ onym: AK-120, BRL-42810, M-5210; Chemical name: 9- [ 4-Acetoxy-3- (acetoxymethyl) butyl] -2-aminopurine; CAS number: 104227-87-4), or any analogues, derivatives, salts, prodrugs, bioprecursors or metabolites of Famciclovir including but not restricted to the salts Famciclovir monohydrate or any phosphate ester and/or acyl derivatives of Famciclovir, or its metabolic active princi- pie compound Penciclovir (Synonym: BRL-39123; Chemical name: 9- [4-Hydroxy-3- (hydroxymethyl) butyl] guanine; CAS number: 39809-25- l),or any analogues, derivatives, salts, prodrugs, bioprecursors or metabolites of Penciclovir, including
  • Famciclovir and Penciclovir are purine nucleoside analogue antiviral compounds, that were originally developed against Her ⁇ pes Simplex Virus (HSV) and Varicella Zoster Virus (VZV) infec ⁇ tions, and their antiviral properties are effected by the inhi ⁇ bition of the respective viral DNA polymerase enzymes.
  • HSV Her ⁇ pes Simplex Virus
  • VZV Varicella Zoster Virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne de nouvelles thérapies pour traiter la douleur et des maladies apparentées, ainsi que des composés pharmaceutiques destinés à être utilisés dans lesdites thérapies.
EP13721770.9A 2012-05-11 2013-05-10 Utilisation de composés pour le traitement de la douleur Withdrawn EP2846788A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13721770.9A EP2846788A1 (fr) 2012-05-11 2013-05-10 Utilisation de composés pour le traitement de la douleur

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12167771 2012-05-11
PCT/EP2013/059752 WO2013167743A1 (fr) 2012-05-11 2013-05-10 Utilisation de composés pour le traitement de la douleur
EP13721770.9A EP2846788A1 (fr) 2012-05-11 2013-05-10 Utilisation de composés pour le traitement de la douleur

Publications (1)

Publication Number Publication Date
EP2846788A1 true EP2846788A1 (fr) 2015-03-18

Family

ID=48407575

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13721770.9A Withdrawn EP2846788A1 (fr) 2012-05-11 2013-05-10 Utilisation de composés pour le traitement de la douleur

Country Status (4)

Country Link
EP (1) EP2846788A1 (fr)
JP (1) JP2015520144A (fr)
AU (1) AU2013257951A1 (fr)
WO (1) WO2013167743A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109651189A (zh) * 2019-01-31 2019-04-19 上海应用技术大学 一种苯甲酰腙类神经氨酸酶抑制剂及其制备方法和用途

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2728135T3 (es) 2011-07-20 2019-10-22 Univ Brigham Young Materiales de hidrogel que incorporan un compuesto de elución de ceragenina
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
WO2014107740A2 (fr) 2013-01-07 2014-07-10 Brigham Young University Méthodes d'inhibition de la prolifération cellulaire et de traitement de certaines maladies
US11524015B2 (en) 2013-03-15 2022-12-13 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
EP2970280B1 (fr) * 2013-03-15 2021-07-07 Brigham Young University Procédés de traitement d'une inflammation, de troubles auto-immunes et de la douleur
US10568893B2 (en) 2013-03-15 2020-02-25 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US11690855B2 (en) 2013-10-17 2023-07-04 Brigham Young University Methods for treating lung infections and inflammation
US20150203527A1 (en) 2014-01-23 2015-07-23 Brigham Young University Cationic steroidal antimicrobials
CA2844321C (fr) 2014-02-27 2021-03-16 Brigham Young University Composes antimicrobiens steroides cationiques
CN105531281B (zh) * 2014-04-21 2017-12-15 四川海思科制药有限公司 一种核苷类似物及其中间体的制备方法
US10238665B2 (en) 2014-06-26 2019-03-26 Brigham Young University Methods for treating fungal infections
US10441595B2 (en) 2014-06-26 2019-10-15 Brigham Young University Methods for treating fungal infections
US10227376B2 (en) 2014-08-22 2019-03-12 Brigham Young University Radiolabeled cationic steroid antimicrobials and diagnostic methods
US10155788B2 (en) 2014-10-07 2018-12-18 Brigham Young University Cationic steroidal antimicrobial prodrug compositions and uses thereof
US10370403B2 (en) 2015-04-22 2019-08-06 Brigham Young University Methods for the synthesis of ceragenins
CN104849388B (zh) * 2015-05-27 2017-02-22 湖北生物医药产业技术研究院有限公司 测定盐酸阿比多尔原料药中有机溶剂残留含量的方法
CN105367602A (zh) * 2015-11-26 2016-03-02 中山大学 阿德福韦酯水杨酸共晶及其制备方法和组合物
CN107849074A (zh) * 2016-01-19 2018-03-27 四川海思科制药有限公司 一种核苷类似物的烷氧烷基酯前药及其应用
CN107011382A (zh) * 2016-01-28 2017-08-04 单爱莲 一种替诺福韦前药及其制备方法
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
CN106117295B (zh) * 2016-06-16 2020-05-22 贵州医科大学 阿德福韦单硫代l-氨基酸酯单胆酸酯衍生物及其制备方法
WO2018039157A1 (fr) * 2016-08-25 2018-03-01 Merck Sharp & Dohme Corp. Promédicaments antiviraux du ténofovir
US10301287B2 (en) 2016-08-31 2019-05-28 Tobira Therapeutics, Inc. Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
KR101841951B1 (ko) * 2016-12-29 2018-03-26 충남대학교 산학협력단 에반스 블루를 포함하는 만성통증 질환 예방 또는 치료용 조성물
US10959433B2 (en) 2017-03-21 2021-03-30 Brigham Young University Use of cationic steroidal antimicrobials for sporicidal activity
WO2018190713A1 (fr) * 2017-04-12 2018-10-18 Umc Utrecht Holding B.V. Inhibiteurs de lysine méthyltransférase destinés au traitement de la douleur
CN107266499B (zh) * 2017-06-05 2019-07-02 珠海优润医药科技有限公司 一种抗病毒化合物及其制备方法
CN109420172B (zh) * 2017-08-30 2021-04-23 新疆医科大学第一附属医院 一种抑制剂在制备治疗囊型包虫病药物方面的用途
KR101833225B1 (ko) 2017-09-26 2018-03-02 주식회사 엠젠플러스 인간 프로인슐린을 발현하는 형질전환 돼지 및 이의 제조방법
US11103465B2 (en) 2017-11-22 2021-08-31 Ted's Brain Science, Inc. Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof
US10624866B2 (en) 2018-03-05 2020-04-21 The Industry & Academic Cooperation In Chungnam National University (Iac) Composition for prevention or treatment of chronic pain comprising Evans blue
JP7402225B2 (ja) * 2018-05-11 2023-12-20 ロード アイランド ホスピタル ヌクレオシド系逆転写酵素阻害剤を用いて関節障害を処置するための組成物および方法
EP3797100A4 (fr) 2018-05-23 2022-06-15 Mor Research Applications Ltd. Inhibiteurs du récepteur 4 de type toll (tlr4) et leur utilisation
CN109776354B (zh) * 2019-01-04 2021-11-19 上海应用技术大学 一种二羟基苯甲酰腙类神经氨酸酶抑制剂及其制备和应用
CN109925248B (zh) * 2019-04-28 2021-10-19 青岛科技大学 一种含有根皮素、三七总皂苷抗皮肤光老化作用的护肤组合物
CN110115244A (zh) * 2019-04-30 2019-08-13 新疆农业大学 一种原花青素对马匹的饲喂方法
PL3871672T3 (pl) * 2020-02-27 2022-09-26 The Procter & Gamble Company Komfreiny – hamujące ekspresję genów prozapalnych lignany arylonaftalenowe oraz kompozycja farmaceutyczna je zawierająca
WO2021223398A1 (fr) * 2020-05-07 2021-11-11 西安新通药物研究股份有限公司 Forme cristalline destinée au traitement d'une maladie hépatique et son utilisation
CN114159450B (zh) * 2020-09-10 2023-10-27 上海交通大学 原人参二醇类化合物在治疗疼痛和成瘾物质躯体依赖、精神依赖和成瘾的用途
KR102541582B1 (ko) * 2020-10-29 2023-06-12 가톨릭관동대학교산학협력단 13-ｏ-아세틸포볼을 포함하는 골질환 및 혈관석회화증 예방 또는 치료용 약학적 조성물
CN113648306A (zh) * 2021-08-16 2021-11-16 西北工业大学 佛手柑素在预防或治疗骨质疏松和/或骨丢失中的应用
WO2023192361A1 (fr) * 2022-03-31 2023-10-05 Incelldx, Inc. Procédés de traitement d'un sujet pour la fibromyalgie et compositions destinées à être utilisées dans ceux-ci
CN114984002B (zh) * 2022-07-25 2023-11-17 山西医科大学 一种式(i)化合物制备镇痛药物中的用途
CN116217576B (zh) * 2023-03-08 2024-06-14 四川大学 一种基于嘌呤骨架的近红外发射荧光分子及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3485225D1 (de) 1983-08-18 1991-12-05 Beecham Group Plc Antivirale guanin-derivate.
EP0152316B1 (fr) 1984-01-26 1989-07-26 Merck & Co. Inc. Butylguanines substituées et leur utilisation dans des compositions antivirales
US5246937A (en) 1985-09-18 1993-09-21 Beecham Group P.L.C. Purine derivatives
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
ES2098219T3 (es) 1987-08-01 1997-05-01 Beecham Group Plc Compuestos de purina y su preparacion.
GB8904855D0 (en) 1989-03-03 1989-04-12 Beecham Group Plc Pharmaceutical treatment
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
DK0481214T3 (da) 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prolægemidler af phosphonater
US5206244A (en) 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
NZ250842A (en) 1991-02-22 1996-03-26 Univ Emory Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc)
IL111138A (en) * 1993-10-05 1997-04-15 Smithkline Beecham Plc Pharmaceutical compositions comprising penciclovir and/or its bioprecursor and/or its derivatives for the treatment and prophylaxis of post-herpetic neuralgia
TW369536B (en) 1996-01-18 1999-09-11 Mitsubishi Chem Corp Phosphonate nucleotide compounds
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
EE200000432A (et) 1998-01-23 2001-12-17 Bayer Aktiengesellschaft Naftüül- ja aniliidasendatud sulfoonamiidid
US7884076B2 (en) * 2003-11-06 2011-02-08 The Trustees Of Columbia University In The City Of New York Multipeptide regimen for the treatment of autistic spectrum, behavioral, emotional and visceral inflammation/autoimmune disorders
US8741332B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for dermally treating neuropathic pain
CN101245068A (zh) 2007-02-14 2008-08-20 浙江医药股份有限公司新昌制药厂 结晶型态的恩替卡韦及其制备方法和其药物组合物及用途
WO2008112715A2 (fr) * 2007-03-12 2008-09-18 Vm Discovery Inc. Nouveaux agents modulateurs des canaux d'ions calcium
CN102048677B (zh) * 2009-11-09 2014-03-05 杭州赛利药物研究所有限公司 一种盐酸缬更昔洛韦固体制剂及其制备方法
CN102093422B (zh) 2009-12-10 2015-02-25 中国人民解放军军事医学科学院毒物药物研究所 无环核苷膦酸酯衍生物及其医药用途
CN101856322B (zh) * 2010-06-11 2011-12-28 中国人民解放军军事医学科学院卫生装备研究所 一种磺胺嘧啶银控释凝胶及制备方法
EA201300558A1 (ru) * 2010-11-11 2013-11-29 Акрон Моликьюлис Гмбх Соединения и способы для купирования боли

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2013167743A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109651189A (zh) * 2019-01-31 2019-04-19 上海应用技术大学 一种苯甲酰腙类神经氨酸酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
JP2015520144A (ja) 2015-07-16
AU2013257951A1 (en) 2015-01-22
WO2013167743A1 (fr) 2013-11-14

Similar Documents

Publication Publication Date Title
EP2846788A1 (fr) Utilisation de composés pour le traitement de la douleur
AU2016244212B2 (en) Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
US20150290235A1 (en) Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
US20090053168A1 (en) Treatments of b-cell proliferative disorders
US20100009934A1 (en) Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
US20040224916A1 (en) Compositions and methods for combination antiviral therapy
US20090047243A1 (en) Combinations for the treatment of b-cell proliferative disorders
WO2022217154A2 (fr) Analogues de nucléosides et de nucléotides modifiés utilisés en tant qu'agents antiviraux contre le coronavirus et d'autres virus
AU2011328009A1 (en) Compounds and methods for treating pain
WO2017007712A1 (fr) Utilisation d'inhibiteurs de trem-1 pour traiter, éliminer et éradiquer l'infection par le vih-1
KR100632520B1 (ko) Β 형 간염 바이러스를 치료하기 위한 복합 요법
US11744831B2 (en) Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
OA12588A (en) DAPD combination therapy with inosine monophosphate dehydrogenase inhibitor.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141210

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150731